JAMES PAUL GRIFFITH
Pilots at Wood Rdg Cir, Cherry Brook, MA
License number
Massachusetts A3148703
Issued Date
Jul 2016
Expiration Date
Jul 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
15 Wood Ridge Cir, Cherry Brook, MA 02493
Professional information
Structure-Based Drug Design Methods For Identifying D-Ala-D-Ala Ligase Inhibitors As Antibacterial Drugs
US Patent:
2007020, Sep 6, 2007
Filed:
Aug 1, 2006
Appl. No.:
11/461678
Inventors:
Paul Ala - Newark DE, US
Janid Ali - Waltham MA, US
Carlos Faerman - Acton MA, US
James Griffith - Weston MA, US
Andrew Magee - Maynard MA, US
Scott Moe - Marlborough MA, US
Manuel Navia - Lexington MA, US
Emanuele Perola - Cambridge MA, US
Patrick Connelly - Harvard MA, US
Janid Ali - Waltham MA, US
Carlos Faerman - Acton MA, US
James Griffith - Weston MA, US
Andrew Magee - Maynard MA, US
Scott Moe - Marlborough MA, US
Manuel Navia - Lexington MA, US
Emanuele Perola - Cambridge MA, US
Patrick Connelly - Harvard MA, US
Assignee:
Pliva d.d. - Zagreb
International Classification:
C12Q 1/25
US Classification:
435007710, 435004000
Abstract:
The invention is based on the discovery that certain small molecules can bind to the ATP binding site of D-Ala-D-Ala ligase, even in the absence of the enzyme's substrate, and can cause a conformational change in the enzyme structure similar to that which occurs upon binding of ATP and substrate to the enzyme. Without wishing to be bound by any theory, it is believed that such a conformational change is required for either activation or inhibition of the enzyme. The information obtained from this discovery has enabled identification of key interactions in the active site of the enzyme, as well as the design and opimization of inhibitors.
Molecules Comprising A Calcineurin-Like Binding Pocket And Encoded Data Storage Medium Capable Of Graphically Displaying Them
US Patent:
7065452, Jun 20, 2006
Filed:
Nov 1, 1999
Appl. No.:
09/431469
Inventors:
David M. Armistead - Maynard MA, US
Matthew James Fitzgibbon - Millis MA, US
Mark Andrew Fleming - Cambridge MA, US
James P. Griffith - Weston MA, US
Eunice E. Kim - Framingham MA, US
Joseph L. Kim - Natick MA, US
Michael D. Sintchak - Winchester MA, US
John Allan Thomson - Belmont MA, US
Keith P. Wilson - Hopkinton MA, US
Matthew James Fitzgibbon - Millis MA, US
Mark Andrew Fleming - Cambridge MA, US
James P. Griffith - Weston MA, US
Eunice E. Kim - Framingham MA, US
Joseph L. Kim - Natick MA, US
Michael D. Sintchak - Winchester MA, US
John Allan Thomson - Belmont MA, US
Keith P. Wilson - Hopkinton MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
G06G 7/48, G06N 7/06
US Classification:
702 27, 703 2
Abstract:
The present invention relates to crystallized molecules and molecular complexes which comprise the active site binding pocket or the FKBP12/FK506 binding pocket of calcineurin or close structural homologues to either binding pocket. This invention also relates to a data storage material encoded with the corresponding structure coordinates of those crystallized molecules or molecular complexes. Such data storage material is capable of displaying such molecules and molecular complexes as a graphical three-dimensional representation on a computer screen. In addition, this invention relates to methods of using the structure coordinates of those molecules or molecular complexes to solve the structure of homologous proteins. This invention also relates to methods of using the structure coordinates to screen and design compounds that bind to calcineurin or homologues thereof.
Molecules Comprising A Calcineurin-Like Binding Pocket And Encoded Data Storage Medium Capable Of Graphically Displaying Them
US Patent:
2007001, Jan 11, 2007
Filed:
Jun 19, 2006
Appl. No.:
11/471290
Inventors:
David Armistead - Maynard MA, US
Matthew Fitzgibbon - Millis MA, US
Mark Fleming - Cambridge MA, US
James Griffith - Weston MA, US
Eunice Kim - Framingham MA, US
Joseph Kim - Natick MA, US
Michael Sintchak - Winchester MA, US
John Thomson - Belmont MA, US
Keith Wilson - Hopkinton MA, US
Matthew Fitzgibbon - Millis MA, US
Mark Fleming - Cambridge MA, US
James Griffith - Weston MA, US
Eunice Kim - Framingham MA, US
Joseph Kim - Natick MA, US
Michael Sintchak - Winchester MA, US
John Thomson - Belmont MA, US
Keith Wilson - Hopkinton MA, US
International Classification:
G06F 19/00, C07K 14/705
US Classification:
702019000, 530350000
Abstract:
The present invention relates to crystallized molecules and molecular complexes which comprise the active site binding pocket or the FKBP12/FK506 binding pocket of calcineurin or close structural homologues to either binding pocket. This invention also relates to a data storage material encoded with the corresponding structure coordinates of those crystallized molecules or molecular complexes. Such data storage material is capable of displaying such molecules and molecular complexes as a graphical three-dimensional representation on a computer screen. In addition, this invention relates to methods of using the structure coordinates of those molecules or molecular complexes to solve the structure of homologous proteins. This invention also relates to methods of using the structure coordinates to screen and design compounds that bind to calcineurin or homologues thereof.
Crystal Structure Of Fms-Like Tyrosine Kinase
US Patent:
7494795, Feb 24, 2009
Filed:
Sep 15, 2004
Appl. No.:
10/941387
Inventors:
James Paul Griffith - Weston MA, US
James Roger Black - Wenham MA, US
Carlos H. Faerman - Acton MA, US
Lovorka Lora Swenson - Belmont MA, US
Michael Andrew Wynn - Salem MA, US
Fan Lu - Newton MA, US
Judith A. Lippke - Chestnut Hill MA, US
Kumkum Saxena - Framingham MA, US
James Roger Black - Wenham MA, US
Carlos H. Faerman - Acton MA, US
Lovorka Lora Swenson - Belmont MA, US
Michael Andrew Wynn - Salem MA, US
Fan Lu - Newton MA, US
Judith A. Lippke - Chestnut Hill MA, US
Kumkum Saxena - Framingham MA, US
International Classification:
C12N 9/10, G01N 31/00
US Classification:
435193, 436 4
Abstract:
The invention relates to FMS-like tyrosine kinase (FLT3), FLT3 binding pockets or FLT3-like binding pockets. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to FMS-like tyrosine kinase protein, complexes of FMS-like tyrosine kinase protein, homologues thereof, or FLT-3-like protein or protein complexes. The invention also relates to crystallizable compositions and crystals comprising an FMS-like tyrosine kinase cytoplasmic domain or homologues thereof. The invention also relates to methods of identifying inhibitors of the cytoplasmic domain of FMS-like tyrosine kinase protein.
Structure-Based Drug Design Methods For Identifying D-Ala-D-Ala Ligase Inhibitors As Antibacterial Drugs
US Patent:
2003011, Jun 26, 2003
Filed:
Jun 28, 2002
Appl. No.:
10/186886
Inventors:
Paul Ala - Newark DE, US
Janid Ali - Waltham MA, US
Carlos Faerman - Acton MA, US
James Griffith - Weston MA, US
Andrew Magee - Maynard MA, US
Scott Moe - Marlborough MA, US
Manuel Navia - Lexington MA, US
Emanuele Perola - Cambridge MA, US
Patrick Connelly - Harvard MA, US
Janid Ali - Waltham MA, US
Carlos Faerman - Acton MA, US
James Griffith - Weston MA, US
Andrew Magee - Maynard MA, US
Scott Moe - Marlborough MA, US
Manuel Navia - Lexington MA, US
Emanuele Perola - Cambridge MA, US
Patrick Connelly - Harvard MA, US
International Classification:
G01N033/53, G06F019/00, G01N033/48, G01N033/50
US Classification:
435/007100, 702/019000
Abstract:
The invention is based on the discovery that certain small molecules can bind to the ATP binding site of D-Ala-D-Ala ligase, even in the absence of the enzyme's substrate, and can cause a conformational change in the enzyme structure similar to that which occurs upon binding of ATP and substrate to the enzyme. Without wishing to be bound by any theory, it is believed that such a conformational change is required for either activation or inhibition of the enzyme. The information obtained from this discovery has enabled identification of key interactions in the active site of the enzyme, as well as the design and opimization of inhibitors.
Molecules Comprising A Calcineurin-Like Binding Pocket And Encoded Data Storage Medium Capable Of Graphically Displaying Them
US Patent:
5978740, Nov 2, 1999
Filed:
Aug 9, 1995
Appl. No.:
8/512815
Inventors:
David M. Armistead - Maynard MA
Matthew James Fitzgibbon - Millis MA
Mark Andrew Fleming - Cambridge MA
James P. Griffith - Weston MA
Eunice E. Kim - Framingham MA
Joseph L. Kim - Natick MA
Michael D. Sintchak - Winchester MA
John Allan Thomson - Belmont MA
Keith P. Wilson - Hopkinton MA
Matthew James Fitzgibbon - Millis MA
Mark Andrew Fleming - Cambridge MA
James P. Griffith - Weston MA
Eunice E. Kim - Framingham MA
Joseph L. Kim - Natick MA
Michael D. Sintchak - Winchester MA
John Allan Thomson - Belmont MA
Keith P. Wilson - Hopkinton MA
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
G06F 1900
US Classification:
702 19
Abstract:
The present invention relates to crystallized molecules and molecular complexes which comprise the active site binding pocket or the FKBP12/FK506 binding pocket of calcineurin or close structural homologues to either binding pocket. This invention also relates to a data storage material encoded with the corresponding structure coordinates of those crystallized molecules or molecular complexes. Such data storage material is capable of displaying such molecules and molecular complexes as a graphical three-dimensional representation on a computer screen. In addition, this invention relates to methods of using the structure coordinates of those molecules or molecular complexes to solve the structure of homologous proteins. This invention also relates to methods of using the structure coordinates to screen and design compounds that bind to calcineurin or homologues thereof.
Crystal Structure And Mutants Of Interleukin-1 Beta Converting Enzyme
US Patent:
5856116, Jan 5, 1999
Filed:
May 25, 1995
Appl. No.:
8/450130
Inventors:
Keith P. Wilson - Hopkinton MA
James P. Griffith - Weston MA
Eunice E. Kim - Framingham MA
David J. Livingston - Newtonville MA
James P. Griffith - Weston MA
Eunice E. Kim - Framingham MA
David J. Livingston - Newtonville MA
Assignee:
Vertex Pharmaceuticals, Incorporated - Cambridge MA
International Classification:
C12Q 137
US Classification:
435 23
Abstract:
Interleukin-1. beta. converting enzyme ("ICE") processes an inactive precursor to the pro-inflammatory cytokine, interleukin-1. beta. The high-resolution structure of human ICE crystallized in complex with an inhibitor is determined by X-ray diffraction. The active site spans both the 10 and 20 kilodalton subunits. The accessory binding site is composed of residues from the p10 and p20 subunits that are adjacent to the two-fold axis of the crystal. The structure coordinates of the enzyme may be used to design novel classes of ICE inhibitors.
Crystal Structure And Mutants Of Interleukin-1.Beta. Converting Enzyme
US Patent:
6057119, May 2, 2000
Filed:
May 25, 1995
Appl. No.:
8/450362
Inventors:
Keith P. Wilson - Hopkinton MA
James P. Griffith - Weston MA
Eunice E. Kim - Framingham MA
David J. Livingston - Newtonville MA
James P. Griffith - Weston MA
Eunice E. Kim - Framingham MA
David J. Livingston - Newtonville MA
Assignee:
Vertex Pharmaceuticals, Incorporated - Cambridge MA
International Classification:
C12Q 137
US Classification:
435 23
Abstract:
Interleukin-1. beta. converting enzyme ("ICE") processes an inactive precursor to the pro-inflammatory cytokine, interleukin-1. beta. The high-resolution structure of human ICE crystallized in complex with an inhibitor is determined by X-ray diffraction. The active site spans both the 10 and 20 kilodalton subunits. The accessory binding site is composed of residues from the p10 and p20 subunits that are adjacent to the two-fold axis of the crystal. The structure coordinates of the enzyme may be used to design novel classes of ICE inhibitors.